Daily Finance - Mar 12, 2010Roche Holding Ltd. (RO)
-
Melly Alazraki
at
Daily FinanceLess than a week after that, AstraZeneca ( ) said that its experimental oncology drug Recentin failed to show any better results than
Roche's ( ) Avastin as a treatment for colon cancer in a late stage, head to head trial. That day,
Roche and Biogen Idec ( ) announced that they were suspending the development of Ocrelizumab for the treatment of rheumatoid arthritis following serious adverse events in studies of the drug, including deaths of patients. That brings us to this week: On Thursday, Pfizer said two Phase 3 trials of Sutent as a treatment for advanced breast cancer did not meet their primary endpoints.
Share:
Less than a week after that, AstraZeneca ( ) said that its experimental oncology drug Recentin failed to show any better results than <span class="company">Roche</span>'s ( ) Avastin as a treatment for colon cancer in a late stage, head to head trial. That day, <span class="company">Roche</span> and Biogen Idec ( ) announced that they were suspending the development of Ocrelizumab for the treatment of rheumatoid arthritis following serious adverse events in studies of the drug, including deaths of patients. That brings us to this week: On Thursday, Pfizer said two Phase 3 trials of Sutent as a treatment for advanced breast cancer did not meet their primary endpoints.
Tweet this